All stock lists
uniQure N.V. (NASDAQ:QURE)
NL · Delayed Price · Currency is USD
Also listed: 0EE0.LHealthcare · Biotechnology
23.87+0.90 (+3.92%)
Market cap
$1.66B
Insider Score
Health Score
Analyst consensus
Listed since
Feb 5, 2014
Website
Insider Score
––Not scored
QURE Insider Score
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
QURE analyst forecast
QURE analyst consensus
Hold3 ratings
Buy 1 Hold 2 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
QURE 12-month price target
$48.00+109.0% upsideaverage of 1 firm
$48.00High
$48.00Low
QURE ratings mix, last 12 months
Buy Hold Sell
Best analysts covering QURE
- HC Wainwright & Co.67%success rate · +68.6% avg return · 18 calls
- RBC Capital67%success rate · +65.2% avg return · 6 calls
- Chardan Capital54%success rate · +48.0% avg return · 13 calls
- Leerink Partners50%success rate · +3.4% avg return · 2 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
QURE analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Barclays | Equal Weight | — | — | Downgraded | 2026-10-05 |
| RBC Capital | Outperform | $48.00 | +105.4% | Reiterated | 2026-10-02 | |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2026-09-30 |
| — | Wolfe Research | Outperform | — | — | Upgraded | 2026-07-30 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-07-30 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-07-30 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-06-29 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-06-25 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-06-18 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2026-06-18 |
| — | Barclays | Overweight | — | — | Upgraded | 2026-06-18 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-06-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-05-06 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2026-04-30 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2026-04-20 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2026-03-23 |
| — | Mizuho | Outperform | — | — | Upgraded | 2026-03-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-10 |
| — | Wells Fargo | Overweight | — | — | Upgraded | 2026-03-09 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2026-03-09 |
| — | RBC Capital | Outperform | — | — | Upgraded | 2026-03-09 |
| — | Mizuho | Neutral | — | — | Downgraded | 2026-03-03 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2026-03-03 |
| — | Wells Fargo | Equal Weight | — | — | Downgraded | 2026-03-03 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2026-03-03 |
| — | Cantor Fitzgerald | Neutral | — | — | Downgraded | 2026-03-02 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-03-02 |
| — | HC Wainwright& Co. | Buy | — | — | Reiterated | 2026-02-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-02-10 |
| — | Stifel | Buy | — | — | Reiterated | 2025-12-11 |
| — | Mizuho | Outperform | — | — | Reiterated | 2025-12-09 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-12-04 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-11-12 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-11-11 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2025-11-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-11-04 |
| — | William Blair | Market Perform | — | — | Downgraded | 2025-11-04 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-11-04 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2025-11-04 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-11-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-10-06 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-10-02 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-09-25 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-09-25 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-09-25 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2025-09-25 |
| — | Mizuho | Outperform | — | — | Reiterated | 2025-09-25 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-09-25 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2025-09-24 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-09-24 |
| — | Stifel | Buy | — | — | Reiterated | 2025-09-24 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-09-08 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-09-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-09-05 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-08-29 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-07-29 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-05-30 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-05-29 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-05-12 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-05-12 |
QURE earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2025-11-10 | -0.85 | -1.38 | $4.8M | $3.7M |
| 2026-03-02 | -0.93 | -0.56 | $5.3M | $5.6M |
| 2026-05-05 | -0.88 | -0.85 | $5.2M | $3.6M |
| 2026-07-29 | -0.82 | -1.22 | $5.4M | $5.8M |
| 2026-11-04Upcoming | -0.92 | — | $6.2M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.